Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group

Cancer. 1990 Sep 1;66(5 Suppl):1045-57. doi: 10.1002/cncr.1990.66.s5.1045.

Abstract

A total of 327 patients with metastatic prostatic cancer were randomized to either bilateral orchiectomy or treatment with zoladex depot supplemented by flutamide 250 mg 3 qid. Statistically significant increases in time to subjective and objective progression were recorded in favor of the combination treatment. No differences in time to death by cancer or overall death were recorded. The clinical significance of these differences will be reassessed once additional follow-up is available and further analysis of the overall clinical material has been carried out.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / secondary
  • Buserelin / administration & dosage
  • Buserelin / analogs & derivatives
  • Flutamide / administration & dosage
  • Goserelin
  • Humans
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Orchiectomy*
  • Prognosis
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Radionuclide Imaging
  • Randomized Controlled Trials as Topic
  • Survival Rate

Substances

  • Goserelin
  • Flutamide
  • Buserelin